153 related articles for article (PubMed ID: 38772155)
1. Exploring new mechanisms of Imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunction.
Li Y; Lou N; Liu X; Zhuang X; Chen S
Biomed Pharmacother; 2024 Jun; 175():116755. PubMed ID: 38772155
[TBL] [Abstract][Full Text] [Related]
2. Imeglimin: the New Kid on the Block.
Shrestha SC; Gupta S
Curr Diab Rep; 2024 Jan; 24(1):13-18. PubMed ID: 38051432
[TBL] [Abstract][Full Text] [Related]
3. Imeglimin: Current Development and Future Potential in Type 2 Diabetes.
Konkwo C; Perry RJ
Drugs; 2021 Feb; 81(2):185-190. PubMed ID: 33247829
[TBL] [Abstract][Full Text] [Related]
4. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
Vuylsteke V; Chastain LM; Maggu GA; Brown C
Drugs R D; 2015 Sep; 15(3):227-32. PubMed ID: 26254210
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis.
Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
J Diabetes Res; 2020; 2020():8768954. PubMed ID: 32215274
[TBL] [Abstract][Full Text] [Related]
6. Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes.
Nowak M; Grzeszczak W
Endokrynol Pol; 2022; 73(2):361-370. PubMed ID: 35381095
[TBL] [Abstract][Full Text] [Related]
7. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model.
Vial G; Chauvin MA; Bendridi N; Durand A; Meugnier E; Madec AM; Bernoud-Hubac N; Pais de Barros JP; Fontaine É; Acquaviva C; Hallakou-Bozec S; Bolze S; Vidal H; Rieusset J
Diabetes; 2015 Jun; 64(6):2254-64. PubMed ID: 25552598
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Johansson KS; Brønden A; Knop FK; Christensen MB
Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and Biological Properties of Imeglimin Hydrochlo ride, A Novel Antidiabetic Agent: A Systematic Review.
Sultan J; Agarwal N; Sharma S
Curr Diabetes Rev; 2024; 20(5):e171023222286. PubMed ID: 37855361
[TBL] [Abstract][Full Text] [Related]
11. Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules.
Sanada J; Obata A; Fushimi Y; Kimura T; Shimoda M; Ikeda T; Nogami Y; Obata Y; Yamasaki Y; Nakanishi S; Mune T; Kaku K; Kaneto H
Sci Rep; 2022 Aug; 12(1):13220. PubMed ID: 35918386
[TBL] [Abstract][Full Text] [Related]
12. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
Pirags V; Lebovitz H; Fouqueray P
Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Hallakou-Bozec S; Vial G; Kergoat M; Fouqueray P; Bolze S; Borel AL; Fontaine E; Moller DE
Diabetes Obes Metab; 2021 Mar; 23(3):664-673. PubMed ID: 33269554
[TBL] [Abstract][Full Text] [Related]
14. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.
Perry RJ; Cardone RL; Petersen MC; Zhang D; Fouqueray P; Hallakou-Bozec S; Bolze S; Shulman GI; Petersen KF; Kibbey RG
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E461-70. PubMed ID: 27406738
[TBL] [Abstract][Full Text] [Related]
15. Imeglimin mitigates the accumulation of dysfunctional mitochondria to restore insulin secretion and suppress apoptosis of pancreatic β-cells from db/db mice.
Aoyagi K; Nishiwaki C; Nakamichi Y; Yamashita SI; Kanki T; Ohara-Imaizumi M
Sci Rep; 2024 Mar; 14(1):6178. PubMed ID: 38485716
[TBL] [Abstract][Full Text] [Related]
16. Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.
Hallakou-Bozec S; Kergoat M; Moller DE; Bolze S
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00193. PubMed ID: 33855202
[TBL] [Abstract][Full Text] [Related]
17. Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using
Fauzi M; Murakami T; Fujimoto H; Botagarova A; Sakaki K; Kiyobayashi S; Ogura M; Inagaki N
Front Endocrinol (Lausanne); 2022; 13():1010825. PubMed ID: 36246910
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and molecular docking studies of new aryl imeglimin derivatives as a potent antidiabetic agent in a diabetic zebrafish model.
Khodakhah A; Mohammadi H; Abdoli S; Zarei I; Palimi M; Ekhtiari Z; Talebi M; Biglar M; Khorramizadeh MR; Amanlou M
Sci Rep; 2024 Apr; 14(1):9410. PubMed ID: 38658742
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
Nagamine J
Nihon Yakurigaku Zasshi; 2023; 158(2):193-202. PubMed ID: 36858505
[TBL] [Abstract][Full Text] [Related]
20. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
